“The doom hung like an anvil over her head. In 2012, a few years after Carol Vincent was diagnosed with non-Hodgkin lymphoma, she was waiting to see whether her cancer would progress enough to require chemotherapy or radiation. The disease had already done a number on her, inflating lymph nodes on her chin, collar bones, and groin. She battled her symptoms while running her own marketing business. To top it all off, she was going through menopause.
“Life is just pointless stress, and then you die,” she thought. “All I’m doing is sitting here waiting for all this shit to happen.””
“Researchers at the Johns Hopkins University School of Medicine have found that a psychedelic drug can significantly reduce anxiety, depression and other emotional distress in cancer patients.
The patients experienced almost immediate relief, which lasted for months, after taking psilocybin, the active hallucinogenic ingredient in “magic mushrooms,” the researchers reported. A separate study by researchers at NYU Langone Medical Center found the same effect.”
“Cancer is a brutal disease on both the body and mind. Not only do treatments like chemotherapy take a massive toll, but the emotional side effects can be hard to bear. Depression and anxiety are high among people with cancer, including those in remission. But two new studies offer promising relief through an unlikely source: hallucinogenic drugs.”
“Patrick Mettes was overcome with frustration. He was anxious.
His bile duct cancer seemed to bring him more anguish than his wife, Lisa Callaghan, ever realized, she said at a news conference Wednesday.
In search of solace, Mettes volunteered for a study in which he was given a synthetic version of psilocybin, a compound found in mind-altering “magic mushrooms,” as a potential treatment for his anxiety and depressed mood.
“In findings that could pry open a door closed for nearly half a century, researchers have found that psilocybin — a hallucinogen long used in traditional healing rituals — eases the depression and soothes the anxiety of patients contending with serious illness and the prospect of imminent death.
In two separate studies published Thursday, researchers report that trial subjects who received a single moderate-to-large dose of psilocybin got substantial and lasting relief from their profound distress. Among 80 cancer patients who participated in the two trials, as many as 4 in 5 continued to feel measurably less hopeless and demoralized six months after taking the drug than they had upon their recruitment.”
Read the full Los Angeles article here
Two randomized controlled trials published today in The Journal of Psychopharmacology report unprecedented findings on the use of psilocybin to dramatically reduce anxiety, depression and existential distress in cancer patients.
These two studies — reviewed and funded by the Heffter Research Institute and conducted by the NYU School of Medicine and Johns Hopkins University — showed that a single dose of psilocybin, in conjunction with psychotherapy, produced rapid, robust and enduring (for more than six months) antianxiety and antidepressant effects in patients with life-threatening cancer diagnoses.
“These findings, the most profound to date in the medical use of psilocybin, indicate it could be more effective at treating serious psychiatric diseases than traditional pharmaceutical approaches, and without having to take a medication every day,” said Heffter Medical Director George Greer.
“The treatment sessions are profoundly moving for patients, and their mystical experiences appear to be linked causally to the dramatic therapeutic responses,” said Roland Griffiths, the principal investigator of the Johns Hopkins study.
“That a drug administered once can have this effect for so long is unprecedented. We have never had anything like it in the psychiatric field,” said Stephen Ross, the principal investigator of the NYU study.
The findings further validate an earlier trial from UCLA, also funded by Heffter and published in 2011 in JAMA Psychiatry, showing similar results in a smaller cohort of patients with terminal cancer.
The recent survey of difficult recreational psilocybin experiences by Heffter Board member and researcher Roland Griffiths, Ph.D. and his team at Johns Hopkins University draws two main conclusions that at first may seem contradictory. On one hand, psilocybin use outside the medical setting occasionally involves traumatic and potentially harmful experiences, as well as occasionally dangerous behaviors. On the other hand, most people report improvements in their quality of life after these difficult experiences.
The medical research setting provides crucial protections from harm that the recreational setting does not: a psychiatric evaluation to exclude subjects with a history of a serious mental disorder that could recur with psilocybin. Another key protection is the presence of specially trained psychotherapists with experience administering psilocybin to support subjects through distressing and confusing experiences, which can happen to anyone in any setting. Finally, the medical research setting provides hours of both pre-session preparation and post-session integration psychotherapy sessions to help the subject maximize the benefit from the session and ensure the positive impacts are enduring.
The relative lack of protections afforded by the recreational setting is apparent in the data. The survey of recreational users found that 24% reported psychological symptoms after their difficult experience, some of which included risky or violent behavior, the need for medical help, and suicide attempts. By comparison, less than 1% of Hopkins medical research subjects experienced enduring psychological symptoms, and no medical research subjects participated in dangerous behavior.
The association of difficult life experiences resulting in personal benefit is well-known and almost goes without saying. Hard work, athletic training, and education are often difficult and yet are widely understood to be effective in helping people improve their lives. But because difficult psilocybin experiences are a rare and different kind of phenomenon in our culture, we don’t associate them with the “no pain, no gain” concept that we are used to hearing about more common life struggles. These survey data appear to confirm that learning from difficulty applies to intense inner experience as well as to the more common difficulties in everyday life.
The findings from this Heffter-funded study also confirm the need to place safety first. Psilocybin is a powerful medicine and it is Heffter’s position that the positive effects found in research to date are most reliably achieved when psilocybin is administered by a doctor with special training and used in a therapeutic setting. Safety has not been demonstrated for psilocybin when used outside of a clinical or laboratory setting, and we caution against recreational use of psilocybin because of potential adverse psychological reactions.
Legendary food writer Michael Pollan explains his interest in psychedelic plants in this podcast interview. Pollan discusses the re-emergence of psilocybin-assisted therapy research after long being suppressed.
Here’s a video from The Atlantic Montlhy about the study at Johns Hopkins using psilocybin for treating long-term smokers.
Psilocybin may help smokers quit the habit by giving them a mystical experience, according to an article in The Atlantic Monthly. In a Heffter-supported study at Johns Hopkins University, 12 of 15 subjects quit smoking after three sessions with the psychedelic substance. Lead researcher Dr. Matthew Johnson suggests that psychedelics may help smokers overcome addiction by changing their self image. “’People will recognize this profound self-worth that they’ve dismissed,’ he said. ‘They look at their life and see themselves as a miracle.’”